Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 7/2012

01.07.2012 | Original article

Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes

verfasst von: Dongmei Lai, Fangyuan Wang, Yifei Chen, Chunhui Wang, Sha Liu, Bufeng Lu, Xirui Ge, Lihe Guo

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer comprises a small population of cancer stem cells (CSCs) that are responsible for tumor maintenance and resistant to cancer therapies, it would be desirable to develop a therapy that could selectively target ovarian CSCs. Recently, cellular immune-based therapies have improved the prognosis of cancer patients clinically. In this study, we isolated a subset of ovarian cancer sphere cells that possess CSC properties and explored the cell cytotoxicity of γδ T cells to ovarian cancer sphere cells using a transwell cocultured cell system. The proliferation rate of the cancer sphere cells decreased to 40% after cocultured with γδ T cells. The γδ T cells increased the sensitivity of SK-OV-3 sphere cells to chemotherapeutic drugs. After the treatment of γδ T cells, the expression of stem cell marker genes decreased in sphere cells, while the expression of HLA-DR antigen on tumor cells was increased in a time-dependent manner. Further, γδ T cells induced G2/M phase cell cycle arrest and subsequent apoptosis in SK-OV-3 sphere cells. Xenograft mouse models demonstrated that γδ T cells dramatically reduced the tumor burden. Notably, the level of IL-17 production significantly increased after cocultured with γδ T cells. We conclude that γδ T cells may efficiently kill ovarian CSCs through IL-17 production and represent a promising immunotherapy for ovarian cancer.
Literatur
1.
Zurück zum Zitat Rufford BD, Jacobs IJ, Menon U (2007) Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 114:59–64PubMed Rufford BD, Jacobs IJ, Menon U (2007) Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 114:59–64PubMed
2.
Zurück zum Zitat Croker K, Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12:374–390PubMedCrossRef Croker K, Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12:374–390PubMedCrossRef
3.
Zurück zum Zitat Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025–3029PubMed Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025–3029PubMed
4.
Zurück zum Zitat Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE et al (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158–166PubMedCrossRef Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE et al (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158–166PubMedCrossRef
5.
Zurück zum Zitat Liu T, Cheng WW, Lai DM, Huang Y (2010) Characterization of primary ovarian cancer cells in different culture system. Oncol Rep 23:1277–1284PubMedCrossRef Liu T, Cheng WW, Lai DM, Huang Y (2010) Characterization of primary ovarian cancer cells in different culture system. Oncol Rep 23:1277–1284PubMedCrossRef
6.
Zurück zum Zitat Ma L, Lai DM, Liu T, Cheng WW, Guo LH (2010) Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SK-OV-3. Acta Biochim Biophys Sin 42:593–602 Ma L, Lai DM, Liu T, Cheng WW, Guo LH (2010) Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SK-OV-3. Acta Biochim Biophys Sin 42:593–602
7.
Zurück zum Zitat Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef
8.
Zurück zum Zitat Galon JA, Costes F, Sanchez-Cabo A, Kirilovsky B, Mlecnik Lagorce-Pages M et al Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964 Galon JA, Costes F, Sanchez-Cabo A, Kirilovsky B, Mlecnik Lagorce-Pages M et al Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964
9.
Zurück zum Zitat Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383–393PubMedCrossRef Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383–393PubMedCrossRef
10.
Zurück zum Zitat Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50PubMedCrossRef Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50PubMedCrossRef
11.
Zurück zum Zitat Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH et al (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27:334–348PubMedCrossRef Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH et al (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27:334–348PubMedCrossRef
12.
Zurück zum Zitat Gao Y, Yang W, Pan M, Scully E, Girardi M et al (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198:433–442PubMedCrossRef Gao Y, Yang W, Pan M, Scully E, Girardi M et al (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198:433–442PubMedCrossRef
13.
Zurück zum Zitat He W, Hao J, Dong S, Gao Y, Tao J et al (2010) Naturally activated Vgamma4 gammadelta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 185:126–133PubMedCrossRef He W, Hao J, Dong S, Gao Y, Tao J et al (2010) Naturally activated Vgamma4 gammadelta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 185:126–133PubMedCrossRef
14.
Zurück zum Zitat Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D et al (1994) Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA 91(17):8175–8179PubMedCrossRef Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D et al (1994) Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA 91(17):8175–8179PubMedCrossRef
15.
Zurück zum Zitat Chen SH, Oki A, Ishikawa S, Ohno T, Mochizuki M et al (1996) Selective proliferation of human γδ T cells in vitro. Cell Res 6(2):177–187CrossRef Chen SH, Oki A, Ishikawa S, Ohno T, Mochizuki M et al (1996) Selective proliferation of human γδ T cells in vitro. Cell Res 6(2):177–187CrossRef
16.
Zurück zum Zitat Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C et al (2001) TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transpl 27:1087–1093CrossRef Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C et al (2001) TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transpl 27:1087–1093CrossRef
17.
Zurück zum Zitat Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P (2002) Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol 215:32–44PubMedCrossRef Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P (2002) Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol 215:32–44PubMedCrossRef
18.
Zurück zum Zitat Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–5885PubMedCrossRef Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–5885PubMedCrossRef
19.
Zurück zum Zitat Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R et al (2011) IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 41:246–251PubMedCrossRef Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R et al (2011) IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 41:246–251PubMedCrossRef
20.
Zurück zum Zitat Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233PubMedCrossRef Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233PubMedCrossRef
21.
Zurück zum Zitat Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651PubMedCrossRef Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651PubMedCrossRef
22.
Zurück zum Zitat Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783PubMedCrossRef Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783PubMedCrossRef
23.
Zurück zum Zitat Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155–158PubMedCrossRef Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155–158PubMedCrossRef
24.
Zurück zum Zitat Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minat N (2001) Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167:5092–5098PubMed Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minat N (2001) Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167:5092–5098PubMed
25.
Zurück zum Zitat Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9 Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 56:1285–1297PubMedCrossRef Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9 Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 56:1285–1297PubMedCrossRef
26.
Zurück zum Zitat Sato KS, Kimura H, Segawa A, Yokota S, Matsumoto J et al (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphos-phonate for cancer immunotherapy. Int J Cancer 116:94–99PubMedCrossRef Sato KS, Kimura H, Segawa A, Yokota S, Matsumoto J et al (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphos-phonate for cancer immunotherapy. Int J Cancer 116:94–99PubMedCrossRef
27.
Zurück zum Zitat Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S et al (2005) Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 174:1338–1347PubMed Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S et al (2005) Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 174:1338–1347PubMed
28.
Zurück zum Zitat Weng D, Song B, Durfee J, Sugiyama V, Wu Z et al (2010) Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer (Epub ahead of print) Weng D, Song B, Durfee J, Sugiyama V, Wu Z et al (2010) Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer (Epub ahead of print)
29.
Zurück zum Zitat Todaro M, D’Asaro M, Caccamo N, Iovino F, Francipane MG et al (2009) Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287–7296PubMedCrossRef Todaro M, D’Asaro M, Caccamo N, Iovino F, Francipane MG et al (2009) Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287–7296PubMedCrossRef
30.
Zurück zum Zitat Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67:5–8PubMedCrossRef Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67:5–8PubMedCrossRef
31.
Zurück zum Zitat Bonneville M, Scotet E (2006) Human Vγ9 Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18:539–546PubMedCrossRef Bonneville M, Scotet E (2006) Human Vγ9 Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18:539–546PubMedCrossRef
32.
Zurück zum Zitat Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M (2009) Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31:321–330PubMedCrossRef Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M (2009) Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31:321–330PubMedCrossRef
33.
Zurück zum Zitat Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, Kuang DM (2011) Interleukin-17-educated monocytes suppress cytotoxic T cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol (Epub ahead of print) Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, Kuang DM (2011) Interleukin-17-educated monocytes suppress cytotoxic T cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol (Epub ahead of print)
Metadaten
Titel
Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes
verfasst von
Dongmei Lai
Fangyuan Wang
Yifei Chen
Chunhui Wang
Sha Liu
Bufeng Lu
Xirui Ge
Lihe Guo
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 7/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1166-4

Weitere Artikel der Ausgabe 7/2012

Cancer Immunology, Immunotherapy 7/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.